Granulocyte Colony Stimulating Factor Treatment For Croh

粒细胞集落刺激因子治疗克罗氏病

• 批准号: 6674077
• 负责人: Peter Mannon
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6674077
• 关键词: Crohn's disease; cellular immunity; clinical research; colony stimulating factor; cytokine; dendritic cells; enzyme linked immunosorbent assay; flow cytometry; gastrointestinal disorder chemotherapy; gastrointestinal pharmacology; helper T lymphocyte; human subject; human therapy evaluation; inflammatory bowel diseases; patient oriented research; polymerase chain reaction; tissue /cell culture

This open-label trial of G-CSF in Crohn's disease seeks to establish the safety and study the efficacy of this drug to induce remission in moderately active disease. We have screened 6 and enrolled 5 subjects in this protocol to date. Responses have ranged from complete remission to no response at all. We are accruing data on changes in cytokine secretion by peripheral and lamina propria mononuclear cells and dendritic cell populations. We are correlating these with clinical parameters including biochemical markers of gut inflammation. Although the data is too preliminary to present definitively at this time, there are interesting trends supporting predictors of response, predictors that could potentially be modified to improve reponse in the future.

这项G-CSF在克罗恩病中的开放标签试验旨在确定该药物在中度活动性疾病中诱导缓解的安全性和有效性。到目前为止，我们在本方案中筛选了6例受试者并入组了5例受试者。反应范围从完全缓解到完全无反应。我们正在积累外周血和固有层单核细胞和树突状细胞群细胞因子分泌变化的数据。我们正在将这些与临床参数（包括肠道炎症的生化标志物）相关联。虽然目前的数据还太初步，无法明确提出，但有一些有趣的趋势支持反应的预测因素，这些预测因素可能会被修改，以改善未来的反应。